Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)

Davidson EJ; Faulkner RL; Sehr P; Pawlita M; Smyth LJ; Burt DJ; Tomlinson AE; Hickling J; Kitchener HC; Stern PL

首页> 外文期刊>Vaccine >Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)

【24h】

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)

机译：TA-CIN（HPV 16 L2E6E7）加强免疫在先前接种过TA-HPV（编码HPV 16/18 E6E7的牛痘病毒）的外阴上皮内瘤形成患者中的作用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Heterologous prime-boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16/18 E6 and E7, in combination with TA-CIN, an HPV 16 L2E6E7 fusion protein, may offer advantages over the use of either agent alone for the immunotherapy of human papillomavirus (HPV) type 16-associated vulval intraepithelial neoplasia (VIN). In the present study, 10 women with HPV 16-positive high grade VIN, previously primed with TA-HPV, received three booster immunisations with TA-CIN. All but one demonstrated HPV 16-specific proliferative T-cell and/or serological responses following vaccination. Three patients additionally showed lesion shrinkage or symptom relief, but no direct correlation between clinical and immunological responses was seen.

机译：采用TA-HPV（一种编码HPV 16/18 E6和E7的牛痘病毒）与TA-CIN（HPV 16 L2E6E7融合蛋白）的异源初免接种时间表可能比单独使用任何一种试剂进行免疫治疗具有优势人乳头瘤病毒（HPV）16型外阴上皮内瘤变（VIN）的检测。在本研究中，10例先前用TA-HPV引发的HPV 16阳性高等级VIN的妇女接受了TA-CIN的三次加强免疫。接种疫苗后，除一个疫苗外，所有疫苗均显示出HPV 16特异性增殖性T细胞和/或血清反应。三名患者另外显示出病变缩小或症状缓解，但未观察到临床和免疫反应之间的直接相关性。

著录项

来源
《Vaccine》 |2004年第22期|共8页
作者
Davidson EJ; Faulkner RL; Sehr P; Pawlita M; Smyth LJ; Burt DJ; Tomlinson AE; Hickling J; Kitchener HC; Stern PL;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类卫生标准、卫生检查、医药管理;
关键词
Adult; Cancer Vaccines adverse effects immunology; Cell Division; Cervical Intraepithelial Neoplasia immunology pathology; DNA; Viral analysis; Enzyme-Linked Immunosorbent Assay; Female; Glutathione Transferase immunology; Human; Immunity; Cellular physiology; Immunization Schedule; Immunization; Secondary; Immunoglobulin G analysis biosynthesis; Interferon Type II metabolism; Papillomavirus; Human immunology; Phytohemagglutinins immunology; Support; Non-U.S. Gov't; T-Lymphocytes immunology metabolism; Vaccinia virus immunology; Vulva pathology;

机译：成人;癌症疫苗不良反应免疫学;细胞分裂;宫颈上皮内瘤变免疫学病理学;DNA;病毒分析;酶联免疫吸附法;女性;谷胱甘肽转移酶免疫学;人;免疫力;细胞生理学;免疫时间表;免疫;次球蛋白;分析生物合成;II型干扰素代谢;乳头瘤病毒;人类免疫学;植物血凝素免疫学;支持;非美国政府;T淋巴细胞免疫学代谢;牛痘病毒免疫学;外阴病理学;

相似文献

外文文献
中文文献
专利

1. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7) [J] . Davidson EJ, Faulkner RL, Sehr P, Vaccine . 2004,第21a22期

机译：TA-CIN（HPV 16 L2E6E7）加强免疫在先前接种过TA-HPV（编码HPV 16/18 E6E7的牛痘病毒）的外阴上皮内瘤形成患者中的作用
2. TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases. [J] . Hibbitts S Current Opinion in Molecular Therapeutics . 2010,第5期

机译：TA-CIN，一种疫苗，其包含重组HPV融合蛋白（HPV16 L2E6E7）的潜在治疗HPV16相关的生殖疾病。
3. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. [J] . Haupt RM, Wheeler CM, Brown DR, International Journal of Cancer =: Journal International du Cancer . 2011,第11期

机译：HPV6 / 11/16/18 L1病毒样颗粒疫苗对患有HPV16 / 18感染的血清反应阳性妇女进展为宫颈上皮内瘤变的影响。
4. Structural Characterization of L1 Virus-Like Particles Used as Antigens in Cervarix~(TM) , the HPV-16 and HPV-18 Vaccine against Cervical Cancer [C] . M. Deschuyteneer, A. Miseur Microscopy and microanalysis.;Microscopy and microanalysis. . -1

机译：用于宫颈癌的Cervarix〜（TM），HPV-16和HPV-18疫苗中用作抗原的L1病毒样颗粒的结构表征
5. Identification and functional analysis of HPV-16 E7 HLA-DR restricted epitopes in patients with cervical neoplasia or cancer. [D] . Warrino, Dominic. 2004

机译：宫颈癌或癌症患者中HPV-16 E7 HLA-DR限制性表位的鉴定和功能分析。
6. The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years [O] . Miriam Nakalembe, Cecily Banura, Proscovia B Namujju, 2014

机译：年龄在10至16岁之间接受过AS04疫苗接种和未接种疫苗的乌干达女孩中抗HPV16 / 18和抗HPV31 / 33/35/45/52/58抗体的水平
7. The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years [O] . Makalembe, Miriam, Banura, Cecily, Namujju, Proscovia, 2014

机译：年龄在10至16岁之间，接受过AS04疫苗接种和未接种疫苗的乌干达女孩中，抗HPV16 / 18和抗HPV31 / 33/35/45/52/58抗体的水平

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)

摘要

著录项

相似文献

相关主题

期刊订阅